Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23285220 | 0.93 | CYP2D6 (0.42) | CYP3A4SIGMAR1CYP2D6TSHR | |
| SCHEMBL23285144 | 0.80 | OPRL1 (0.44) | OPRL1POLBCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL23274946 | 0.75 | OPRL1 (0.50) | OPRL1POLBCYP3A4HSD17B10CHRNA7 | |
| SCHEMBL23285142 | 0.72 | OPRM1 (0.50) | OPRL1CYP3A4HSD17B10SIGMAR1TMEM97 | |
| SCHEMBL2604321 | 0.71 | OPRM1 (0.56) | OPRL1POLBCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL23285224 | 0.70 | OPRM1 (0.45) | OPRL1POLBCYP3A4HSD17B10CHRNA7 | |
| SCHEMBL23285196 | 0.69 | CYP2D6 (0.44) | CYP3A4SIGMAR1CYP2D6TSHR | |
| SCHEMBL12406592 | 0.69 | OPRL1 (0.46) | OPRL1POLBCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL9177696 | 0.68 | OPRL1 (0.51) | OPRL1POLBCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL9177408 | 0.68 | OPRL1 (0.48) | OPRL1POLBCYP3A4HSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | OPRL1 1846/4885POLB 2598/4885CYP3A4 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.